Insights Newsletter August 2025: Emerging Trends for Clinical Leadership

This month’s Insights Newsletter covers the latest practice-changing pharmacy updates, emerging trends, and popular natural medicine topics and resources. 

Keep Potential Eye Risks With GLP-1 Agonists in Sight

GLP-1 agonists, such as semaglutide, have been linked to rare eye conditions – neovascular age-related macular degeneration (nAMD) and nonarteritic ischemic anterior optic neuropathy (NAION). Our article discusses the frequency of these eye conditions, their potential connection to prolonged use, and the need for further research. We provide guidance on monitoring, including baseline and annual eye exams, and emphasize the importance of reporting vision changes promptly. Finally, we offer recommendations for managing patients experiencing eye issues while on these medications. Readers can customize their own comparison of meds in this class with our new resource GLP-1 and GIP/GLP-1 Agonist Interactive Comparison Chart. Read More

Community Pharmacies: Put Testosterone Claims to the Test

Questions and myths about testosterone replacement therapy are common. Our article clarifies its appropriate use for men with symptoms and confirmed low testosterone levels, debunking misconceptions such as treatment for aging-related low T or the superiority of injections. Your team can use this information to educate patients on therapy options, including product differences like costs and administration, and address concerns about cardiovascular risks. Additionally, we discuss precautions to prevent topical testosterone transfer to others. For further insights, readers can stay tuned for our September 2025 Rumor vs Truth podcast where our editors will demystify other clinical claims about testosterone. Read More

Hospitals: Keep a Pulse on Landiolol for Arrhythmias

Your team will start to hear about landiolol (Rapiblyk), a new IV beta-blocker for atrial tachyarrhythmias such as atrial fibrillation. Our article compares landiolol to esmolol, noting its faster onset, shorter half-life, and higher beta-1 selectivity, which may reduce effects on cardiac output and blood pressure. We also address its high cost, limited indication for use under 24 hours, and similar adverse effects and contraindications to other beta-blockers.  And we provide guidance on its role in therapy, dosing, and preparation. Readers can get our landiolol quick skim graphic for a snapshot of dosing, administration, side effects, and more. Read More

Natural Medicines: Anaphylaxis Linked to Popular Supplements

Several popular supplements have been linked to anaphylaxis. People often view supplements as safer than prescription and OTC drugs, making this a potential “hidden risk.” Our NatMed article reviews 3 popular ingredients with known anaphylaxis and allergy concerns, including Andrographis, echinacea, and soy. We advise caution, particularly in children and patients with existing allergies.  Read More

Pharmacy & Prescriber Podcasts

Medication Talk

Listen to this month’s podcast episode, HIV Prevention: A Guide to PrEP and PEP, as our expert panel explores the latest pharmacologic strategies for HIV prevention—before and after exposure. You’ll listen to panelists break down key considerations for PrEP and PEP, including indications, drug selection, dosing, and monitoring. 

All Medication Talk episodes offer CE credit to Pharmacist’s Letter and Prescriber Insights subscribers for 2 years after the episode release date. Go to the CE/CME & Training Organizer and search “podcast” to find available courses.  

Rumor vs Truth

Your trusted source for facts, where we dissect the evidence behind risky rumors and reveal clinical truths. This new podcast series is designed to help pharmacists, pharmacy technicians, prescribers, and even patients navigate some of the claims they might see about medication therapy. Our newest episode will be released on August 19th. In the meantime, check out our past episodes here.

Clinical Capsules

Listen to our latest episode, Zepbound for Zzz’s: Exploring Tirzepatide for Sleep Apnea, as TRC Healthcare editor, Sara Klockars, PharmD, BCPS unpacks the newly approved use of tirzepatide (Zepbound) for obstructive sleep apnea (OSA)—a first-in-class pharmacologic option for a condition long managed with devices and lifestyle changes. 

Upcoming Tradeshows

We have a packed tradeshow schedule this year and would love to meet with you in person! Send us a meeting request if you’ll be attending any of these shows. 

Check out where we’ll be in the coming months: 

• NACDSTSE25: August 23-25
• HCP Hospital Pharmacy Fall Reverse Expo: September 29 – October 1
• ANCC Magnet/Pathway Conference: October 8-10
• ASHP Midyear: December 7-11 

See the Full List of Events for 2025 

New Blog! Compounding Chronicles

We ALWAYS Wait 30 Minutes After PEC Start-Up

By Adam West, Course and Curriculum Manager at CriticalPoint.

For years, compounders have been told to wait 30 minutes to start compounding after powering up a PEC. But is that really necessary? In this month’s Compounding Chronicles blog, CriticalPoint explores the pharmacy tradition behind the “30-minute rule” and reveals how quickly ISO 5 conditions can actually be restored. Spoiler: you might be waiting for no reason.

Read the Blog

Other Covered Topics

Explore our popular clinical resources, learn about NetCE’s newly expanded Behavioral Health Solution, that makes it easy to deliver scalable, evidence-based CE and compliance training across your team and register for a Bula webinar on 2025 Trends in Pharmacy Legislation and Regulation.